Physician profile
Edward Wang
NPI 1972558666
$3,476.58
in general payments reported to CMS, 2019-2025
33 companies · $667 in 2025
The $667 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,370 · 2021: $203 · 2022: $405 · 2023: $406 · 2024: $425 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.15 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $975.17 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Astellas Pharma US INC | $469.79 | 2019-2025 | Padcev, Xtandi |
| Procept Biorobotics Corporation | $454.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $224.85 | 2019-2024 | Lynparza |
| Ferring Pharmaceuticals INC. | $158.48 | 2019 | |
| Pfizer INC. | $149.58 | 2019-2025 | |
| Accord Healthcare, INC. | $144.88 | 2024-2025 | |
| Boston Scientific Corporation | $107.21 | 2019-2021 | |
| Emd Serono, INC. | $105.76 | 2023 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $86.84 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $65.14 | 2019 | |
| Eisai INC. | $44.97 | 2021-2025 | |
| Progenics Pharmaceuticals, INC. | $42.58 | 2023 | Pylarify |
| Cleerly, INC. | $41.69 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Urogen Pharma, INC. | $36.06 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.37 | 2021 | |
| Antares Pharma, INC. | $30.02 | 2019 | |
| Ambu INC. | $29.29 | 2021 | |
| Puma Biotechnology, INC. | $28.38 | 2022 | |
| Coloplast Corp | $25.46 | 2023 | Titan |
| Teleflex LLC | $25.32 | 2025 | Barrigel |
| Merck Sharp & Dohme LLC | $22.64 | 2021 | |
| Palette Life Sciences, INC. | $21.13 | 2023 | |
| Myriad Genetic Laboratories, INC. | $20.32 | 2022 | |
| Abbvie INC. | $19.75 | 2019 | |
| Incyte Corporation | $19.04 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.18 | 2022 | |
| 180 Medical, INC. | $16.60 | 2019 | |
| Sagent Pharmaceuticals | $15.31 | 2019 | |
| Endo Pharmaceuticals INC. | $13.47 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $12.62 | 2019 | |
| Photocure INC | $12.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.